Ennaid Therapeutics is a global biopharmaceutical company using its unique, patented platform technology to safely and rapidly develop and commercialize therapeutics for infectious diseases. The Company’s lead compound, ETX-101, is an inhibitory peptide that inhibits all four strains of dengue virus…
Ennaid Therapeutics is a global biopharmaceutical company using its unique, patented platform technology to safely and rapidly develop and commercialize therapeutics for infectious diseases. The Company’s lead compound, ETX-101, is an inhibitory peptide that inhibits all four strains of dengue virus, a mosquito-borne tropical disease that causes Dengue Fever, Dengue Hemorrhagic Fever or Dengue Shock Syndrome.
We are accelerating the development and commercialization of a novel therapeutic that inhibits all four strains of Dengue virus followed by West Nile virus.
Based on the discovery of their peptides, they are accelerating the development of a novel therapeutic that inhibits all four strains of Dengue virus. Using this same technological platform, they will focus on accelerating the development of a therapeutic that inhibits West Nile virus, as their company progresses.
In addition to Infectious Diseases, Ennaid Therapeutics will continue to build a rich development pipeline to accelerate the development of other therapeutics that target rare and seemingly incurable diseases in Regenerative Medicine, Oncology, Autoimmune Disorders and Diseases of the Eye, to name a few.
Their team is comprised of seasoned pharmaceutical executives, scientists and business development professionals with a wealth of experience in the life sciences and other industries.
Team (1)
Sectors Ennaid Therapeutics serves:
Health Care
Life Sciences
Join Axial's Private M&A Platform
Ennaid Therapeutics connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
